A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Weina Sun, Yonghong Liu, Fatima Amanat, Irene González-Domínguez, Stephen McCroskery, Stefan Slamanig, Lynda Coughlan, Victoria Rosado, Nicholas Lemus, Sonia Jangra, Raveen Rathnasinghe, Michael Schotsaert, Jose L. Martinez, Kaori Sano, Ignacio Mena, Bruce L. Innis, Ponthip Wirachwong, Duong Huu Thai, Ricardo Das Neves Oliveira, Rami Scharf, Richard Hjorth, Rama Raghunandan, Florian Krammer, Adolfo García-Sastre and Peter Palese ()
Additional contact information
Weina Sun: Icahn School of Medicine at Mount Sinai
Yonghong Liu: Icahn School of Medicine at Mount Sinai
Fatima Amanat: Icahn School of Medicine at Mount Sinai
Irene González-Domínguez: Icahn School of Medicine at Mount Sinai
Stephen McCroskery: Icahn School of Medicine at Mount Sinai
Stefan Slamanig: Icahn School of Medicine at Mount Sinai
Lynda Coughlan: University of Maryland School of Medicine, Department of Microbiology and Immunology
Victoria Rosado: Icahn School of Medicine at Mount Sinai
Nicholas Lemus: Icahn School of Medicine at Mount Sinai
Sonia Jangra: Icahn School of Medicine at Mount Sinai
Raveen Rathnasinghe: Icahn School of Medicine at Mount Sinai
Michael Schotsaert: Icahn School of Medicine at Mount Sinai
Jose L. Martinez: Icahn School of Medicine at Mount Sinai
Kaori Sano: Icahn School of Medicine at Mount Sinai
Ignacio Mena: Icahn School of Medicine at Mount Sinai
Bruce L. Innis: PATH, Center for Vaccine Access and Innovation
Ponthip Wirachwong: The Government Pharmaceutical Organization
Duong Huu Thai: Institute of Vaccines and Medical Biologicals
Ricardo Das Neves Oliveira: Instituto Butantan
Rami Scharf: PATH, Center for Vaccine Access and Innovation
Richard Hjorth: PATH, Center for Vaccine Access and Innovation
Rama Raghunandan: PATH, Center for Vaccine Access and Innovation
Florian Krammer: Icahn School of Medicine at Mount Sinai
Adolfo García-Sastre: Icahn School of Medicine at Mount Sinai
Peter Palese: Icahn School of Medicine at Mount Sinai

Nature Communications, 2021, vol. 12, issue 1, 1-14

Abstract: Abstract Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation of vaccines is necessary to limit the global impact of the COVID-19 pandemic and the emergence of additional variants of concern. We have developed a COVID-19 vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show that the NDV vector expressing an optimized spike antigen (NDV-HXP-S) is a versatile vaccine inducing protective antibody responses. NDV-HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine. We show that NDV-HXP-S GMP-produced in Vietnam, Thailand and Brazil is effective in the hamster model. Furthermore, we show that intramuscular vaccination with NDV-HXP-S reduces replication of tested variants of concerns in mice. The immunity conferred by NDV-HXP-S effectively counteracts SARS-CoV-2 infection in mice and hamsters.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26499-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26499-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26499-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().